Thiostrepton reportedly enhances sensitivity to platinum in vitro and in vivo.44 It has also been reported that cisplatin treatment significantly increases the proportion of CD133+ cells through the Notch signal pathway, and CD133+ cells are related to an increase in cross‐drug resistance to paclitaxel and doxorubicin.26 Therefore, the reduction in CD133+/Oc4‐4A+ cell populations in NSCLC by thiostrepton treatment (Figure 3) provides further support for a role for thiostrepton in combination with chemo‐ and/or target therapeutic agents in preventing drug resistance. This evidence concerns the gene PROM1 and non-small cell lung carcinoma.